Posted inInfectious Diseases news Public Health
Oral Zoliflodacin Proves Non-Inferior to Standard Dual Therapy for Gonorrhoea: A Milestone in Antimicrobial Resistance Management
This phase 3 trial demonstrates that oral zoliflodacin is a viable, non-inferior alternative to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhoea, offering a critical solution to rising antibiotic resistance.